

Dr. Reddy's launches Hepatitis E vaccine in India

The company has partnered with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for marketing and distribution of Hevaxin in India.



Hyderabad: Dr. Reddy's Laboratories has announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India.

Designed for adults aged 18 to 65 years, Hevaxin has demonstrated provides long-lasting immunity, with an established tolerability profile and is stated to be the only approved vaccine against HEV infection in India

The company has partnered with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for marketing and distribution of Hevaxin in India.

Commenting on the announcement, M.V. Ramana, CEO, Branded Markets (India and Emerging Markets), Dr. Reddy's, said: "Hepatitis E remains a serious threat to patients with chronic liver disease and with this introduction, we aim to provide a first-in-class preventive option and support the National Viral Hepatitis Control Programme, under the Ministry of Health to reduce the morbidity and mortality associated with Hepatitis E in India

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/dr-reddys-launches-hepatitis-e-vaccine-in-india/126384931>